Treatment outcome and toxicity of intensity-modulated (chemo) radiotherapy in stage III non-small cell lung cancer patients

Radiation Oncology

Volumn 7, Issue 1, 2012, Pages

  Govaert, Stephanie L A ^a   Troost, Esther G C ^a   Schuurbiers, Olga C J ^a   de Geus Oei, Lioe Fee ^a   Termeer, Ariën ^b   Span, Paul N ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

Intensity modulated (chemo)radiotherapy; Stage III non small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; NARCOTIC ANALGESIC AGENT;

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMORADIOTHERAPY; ESOPHAGUS INJURY; FEMALE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; RADIATION DOSE; RADIATION INJURY; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; COHORT STUDIES; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84865817651     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-7-150     Document Type: Article

References (33)

1. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Book SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) 2012, National Cancer Institute, City.
2. Robinson LA, Ruckdeschel JC, Wagner H, Stevens CW. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:243S-265S. 10.1378/chest.07-1379, 17873172.
3. Jett JR, Schild SE, Keith RL, Kesler KA. Treatment of non-small cell lung cancer, stage IIIB: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:266S-276S. 10.1378/chest.07-1380, 17873173.
4. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007, 132:234S-242S. 10.1378/chest.07-1378, 17873171.
5. Auperin A, Le Pechoux C, Rolland E, Curran WJ, Furuse K, Fournel P, Belderbos J, Clamon G, Ulutin HC, Paulus R, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:2181-2190. 10.1200/JCO.2009.26.2543, 20351327.
6. De Ruysscher D, Botterweck A, Dirx M, Pijls-Johannesma M, Wanders R, Hochstenbag M, Dingemans AM, Bootsma G, Geraedts W, Simons J, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol 2009, 20:98-102.
7. Perez CA, Bauer M, Edelstein S, Gillespie BW, Birch R. Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys 1986, 12:539-547. 10.1016/0360-3016(86)90061-1, 3009368.
8. Rengan R, Rosenzweig KE, Venkatraman E, Koutcher LA, Fox JL, Nayak R, Amols H, Yorke E, Jackson A, Ling CC, Leibel SA. Improved local control with higher doses of radiation in large-volume stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 60:741-747. 10.1016/j.ijrobp.2004.04.013, 15465190.
9. Wang L, Correa CR, Zhao L, Hayman J, Kalemkerian GP, Lyons S, Cease K, Brenner D, Kong FM. The effect of radiation dose and chemotherapy on overall survival in 237 patients with Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2009, 73:1383-1390. 10.1016/j.ijrobp.2008.06.1935, 3381887, 18929449.
10. Belderbos JS, Heemsbergen WD, De Jaeger K, Baas P, Lebesque JV. Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:126-134. 10.1016/j.ijrobp.2006.04.034, 16904518.
11. van Baardwijk A, Wanders S, Boersma L, Borger J, Ollers M, Dingemans AM, Bootsma G, Geraedts W, Pitz C, Lunde R, et al. Mature results of an individualized radiation dose prescription study based on normal tissue constraints in stages I to III non-small-cell lung cancer. J Clin Oncol 2010, 28:1380-1386. 10.1200/JCO.2009.24.7221, 20142596.
12. Kong FM, Hayman JA, Griffith KA, Kalemkerian GP, Arenberg D, Lyons S, Turrisi A, Lichter A, Fraass B, Eisbruch A, et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 2006, 65:1075-1086. 10.1016/j.ijrobp.2006.01.051, 16647222.
13. Nakayama H, Satoh H, Kurishima K, Ishikawa H, Tokuuye K. High-dose conformal radiotherapy for patients with stage III non-small-cell lung carcinoma. Int J Radiat Oncol Biol Phys 2010, 78:645-650. 10.1016/j.ijrobp.2009.08.037, 20869582.
14. Christian JA, Bedford JL, Webb S, Brada M. Comparison of inverse-planned three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67:735-741. 10.1016/j.ijrobp.2006.09.047, 17187941.
15. RTOG Acute Radiation Morbidity Scoring Criteria http://www.rtog.org/ResearchAssociates/AdverseEventReporting/AcuteRadiationMorbidityScoringCriteria.aspx.
16. Yom SS, Liao Z, Liu HH, Tucker SL, Hu CS, Wei X, Wang X, Wang S, Mohan R, Cox JD, Komaki R. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:94-102. 10.1016/j.ijrobp.2006.12.031, 17321067.
17. Liao ZX, Komaki RR, Thames HD, Liu HH, Tucker SL, Mohan R, Martel MK, Wei X, Yang K, Kim ES, et al. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2010, 76:775-781. 10.1016/j.ijrobp.2009.02.032, 19515503.
18. Scrimger RA, Tome WA, Olivera GH, Reckwerdt PJ, Mehta MP, Fowler JF. Reduction in radiation dose to lung and other normal tissues using helical tomotherapy to treat lung cancer, in comparison to conventional field arrangements. Am J Clin Oncol 2003, 26:70-78. 10.1097/00000421-200302000-00014, 12576928.
19. Liu HH, Wang X, Dong L, Wu Q, Liao Z, Stevens CW, Guerrero TM, Komaki R, Cox JD, Mohan R. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004, 58:1268-1279. 10.1016/j.ijrobp.2003.09.085, 15001272.
20. Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50). Book Prescribing, Recording, and Reporting Photon Beam Therapy (Report 50) 1993, International Commission on Radiation Units & Measurements, City.
21. Prescribing, Recording and Reporting Photon Beam Therapy (Report 62); Supplement to ICRU Report 50. Book Prescribing, Recording and Reporting Photon Beam Therapy (Report 62); Supplement to ICRU Report 50 1999, International Commission on Radiation Units and Measurements, City.
22. de Boer HC, Heijmen BJ. A protocol for the reduction of systematic patient setup errors with minimal portal imaging workload. Int J Radiat Oncol Biol Phys 2001, 50:1350-1365. 10.1016/S0360-3016(01)01624-8, 11483348.
23. Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008, 87:17-23. 10.1016/j.radonc.2008.02.005, 2722446, 18343515.
24. Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm - ctc_30.
25. Fenwick JD, Nahum AE, Malik ZI, Eswar CV, Hatton MQ, Laurence VM, Lester JF, Landau DB. Escalation and intensification of radiotherapy for stage III non-small cell lung cancer: opportunities for treatment improvement. Clin Oncol (R Coll Radiol) 2009, 21:343-360.
26. Bortfeld T, Jokivarsi K, Goitein M, Kung J, Jiang SB. Effects of intra-fraction motion on IMRT dose delivery: statistical analysis and simulation. Phys Med Biol 2002, 47:2203-2220. 10.1088/0031-9155/47/13/302, 12164582.
27. Duan J, Shen S, Fiveash JB, Popple RA, Brezovich IA. Dosimetric and radiobiological impact of dose fractionation on respiratory motion induced IMRT delivery errors: a volumetric dose measurement study. Med Phys 2006, 33:1380-1387. 10.1118/1.2192908, 16752574.
28. Jiang SB, Pope C, Al Jarrah KM, Kung JH, Bortfeld T, Chen GT. An experimental investigation on intra-fractional organ motion effects in lung IMRT treatments. Phys Med Biol 2003, 48:1773-1784. 10.1088/0031-9155/48/12/307, 12870582.
29. Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, Oetzel D, Spahn U, Graham MV, Drzymala RE, et al. Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 1998, 42:1-9.
30. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys 2001, 51:880-914.
31. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006, 65:1-7. 10.1016/j.ijrobp.2006.01.027, 16618572.
32. Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, Lubin JH, Preston DL, Preston RJ, Puskin JS, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci USA 2003, 100:13761-13766. 10.1073/pnas.2235592100, 283495, 14610281.
33. Hoffmann AL, Troost EG, Huizenga H, Kaanders JH, Bussink J. Individualized Dose Prescription for Hypofractionation in Advanced Non-Small-Cell Lung Cancer Radiotherapy: an in silico Trial. Int J Radiat Oncol Biol Phys 2012, 83:1596-1602. 10.1016/j.ijrobp.2011.10.032, 22245206.